Prescription Pricing for the People Act of 2025

Bill Number: S. 527
Origin Chamber: Senate
Congress: 119th Congress, Session 1
Policy Area: Commerce
Status: Introduced
Latest Action: 2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
Last Updated: 2026-07-01T15:15:19Z

AI-Generated Summary

Purpose of the Legislation

The Prescription Pricing for the People Act of 2025 (S. 527) aims to address rising prescription drug costs by directing the Federal Trade Commission (FTC) to investigate the role of intermediaries—such as pharmacy benefit managers (PBMs), which are companies that manage prescription drug benefits for insurers and employers—in the pharmaceutical supply chain. The goal is to examine how these intermediaries affect competition, pricing, and access to medications, and to provide Congress with recommendations to promote transparency, fair competition, and cost savings for consumers.

Key Provisions

Definitions (Section 2): Defines key terms, including "appropriate committees of Congress" (the Senate and House Judiciary Committees) and "Commission" (the FTC).
Study of Intermediaries and Merger Activity (Section 3):
Requires the FTC to submit a comprehensive report to Congress within 1 year of enactment, covering:
Practices of PBMs, such as charging payers (e.g., insurers) higher prices than they reimburse independent pharmacies, steering patients to affiliated pharmacies for competitive gain, using proprietary data from non-owned pharmacies to boost their own revenue, and designing drug formularies (lists of covered medications) to favor higher-cost drugs over lower-cost options (after accounting for rebates and discounts).
Trends in competition within the healthcare supply chain, focusing on how intermediaries integrate with drug suppliers, payers, and other entities.
How companies and payers evaluate the benefits, costs, and risks of working with intermediaries like pharmacy services administrative organizations (groups that provide administrative support to pharmacies), and whether more public information on these roles is needed.
Legal or regulatory barriers preventing the FTC from enforcing antitrust (competition) and consumer protection laws in the pharmaceutical supply chain, including the PBM market.
Any legal or regulatory issues that drive up prescription drug prices.
The report must include observations from the FTC's 2017 roundtable on prescription drug market competition, planned FTC actions (e.g., further research, enforcement, or consumer education), and policy/legislative recommendations to enhance transparency, deter anticompetitive behavior, and ensure consumers benefit from efficiencies in mergers or consolidations.
An interim report with progress updates and preliminary findings must be submitted within 180 days of enactment.
Report on Anticompetitive Conduct by Drug Manufacturers (Section 4): Requires a separate FTC report detailing:
The number and types of complaints about anticompetitive actions by manufacturers of "sole-source" drugs (medications with no generic alternatives).
The FTC's current ability to pursue enforcement against these manufacturers.
Recommendations to bolster enforcement against such behavior.

Significant Changes to Existing Law

This bill introduces new mandatory reporting and study requirements for the FTC, which previously had no specific statutory obligation to conduct this level of analysis on pharmaceutical intermediaries and sole-source drugs. It does not amend existing laws directly but could influence future legislation or FTC rulemaking based on its findings and recommendations, potentially expanding antitrust oversight in the drug supply chain.

Potential Impacts

On Government Agencies: The FTC will face increased workload and resource demands to complete the studies and reports, potentially leading to enhanced enforcement tools if recommendations are adopted.
On Citizens: Could indirectly lower prescription drug costs and improve access by identifying and addressing practices that inflate prices, benefiting patients, especially those relying on insurance or government programs like Medicare.
On International Relations: Minimal direct impact, though findings on global supply chain dynamics (e.g., drug manufacturing) might inform U.S. trade policies affecting pharmaceutical imports/exports.
Broader Economy: May promote fairer competition in a $500+ billion industry, potentially reducing healthcare spending for employers, insurers, and taxpayers.

Main Stakeholders Affected

Pharmacy Benefit Managers (PBMs) and Intermediaries: Subject to scrutiny of their pricing, steering, data use, and formulary practices, which could lead to regulatory changes.
Pharmacies: Independent pharmacies may benefit from investigations into unfair reimbursements or data misuse, while affiliated pharmacies could face restrictions on patient steering.
Drug Manufacturers: Producers of sole-source drugs will be examined for anticompetitive conduct, potentially facing stronger FTC actions.
Payers and Insurers: Health plans and employers may gain better insights into intermediary costs and risks, enabling more informed contracting.
Consumers and Patients: Primary beneficiaries through potential price reductions and increased transparency in drug benefits.
Congress and Policymakers: Receive actionable data to shape future laws on drug pricing and competition.
Federal Trade Commission: Gains a formal mandate to study and recommend actions in this sector.

Notable Legal, Constitutional, or Political Implications

Legal Implications: Strengthens the FTC's role in antitrust enforcement under laws like the Federal Trade Commission Act by highlighting enforcement gaps, potentially paving the way for rules on data privacy or pricing transparency in healthcare without directly challenging existing statutes.
Constitutional Implications: Aligns with Congress's commerce clause authority to regulate interstate markets like pharmaceuticals; no apparent conflicts with free speech or due process, as it focuses on studies rather than penalties.
Political Implications: Bipartisan support (introduced by senators from both parties) reflects broad concern over drug affordability, which could build momentum for reforms amid ongoing debates on healthcare costs. Recommendations might influence election-year priorities or budget allocations for FTC enforcement.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Grassley, Chuck [R-IA]

Cosponsors (13)

Sen. Cantwell, Maria [D-WA], Sen. Marshall, Roger [R-KS], Sen. Welch, Peter [D-VT], Sen. Tuberville, Tommy [R-AL], Sen. Coons, Christopher A. [D-DE], Sen. Tillis, Thomas [R-NC], Sen. Blumenthal, Richard [D-CT], Sen. Capito, Shelley Moore [R-WV], Sen. Hirono, Mazie K. [D-HI], Sen. Lankford, James [R-OK], Sen. Boozman, John [R-AR], Sen. Blackburn, Marsha [R-TN], Sen. Warnock, Raphael G. [D-GA]

Recent Actions

2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
2025-04-10: Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
2025-04-10: Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
2025-04-03: Committee on the Judiciary. Ordered to be reported without amendment favorably.
2025-02-11: Read twice and referred to the Committee on the Judiciary.
2025-02-11: Introduced in Senate

Bill Versions

Prescription Pricing for the People Act of 2025 — issued 2025-02-11 — PDF (6 pages)
Prescription Pricing for the People Act of 2025 — issued 2025-04-10 — PDF (8 pages)